.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists have identified a schizophrenia biomarker for cognition that may revolutionize treatment for the disorder. Currently, most medications focus on hallucinations but overlook cognitive deficits. This lack of treatment for executive dysfunction often prevents patients from integrating into society.
Researchers from Northwestern University analyzed the cerebrospinal fluid of over 100 participants. They found reduced levels of a protein called Cacna2d1 in patients with schizophrenia. This protein plays a vital role in maintaining the balance of brain circuits. When levels drop, circuits become overexcited, leading to cognitive symptoms like disorganized thinking.
To address this deficiency, the research team developed a synthetic version of the protein named SEAD1. During trials on mouse models, a single injection corrected abnormal brain activity. It also restored behavioral problems without significant side effects. Consequently, this approach offers hope for a targeted peptide therapy. Moreover, this discovery allows clinicians to identify a specific subgroup of patients likely to respond to the drug. Because of this, it moves psychiatry closer to the precision medicine models used in other chronic diseases.
The restoration of synaptic plasticity could benefit other disorders, including depression. Furthermore, researchers aim to develop a less invasive blood-based assay for easier monitoring. Although long-term effects are unknown, the initial results mark a significant step forward in neuroscience. In addition, the team is working to optimize the delivery of SEAD1 for human use.
Q1: What is the new biomarker identified for schizophrenia?
The biomarker is a freely circulating form of the brain protein called 'Cacna2d1,' which is found at reduced levels in patients with cognitive symptoms.
Q2: How does the SEAD1 drug work to treat symptoms?
SEAD1 is a synthetic peptide that mimics the Cacna2d1 protein. It helps recalibrate overexcited brain circuits and restore synaptic plasticity to improve cognitive function.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Northwestern University researchers identify the Cacna2d1 protein as a biomarker for cognitive symptoms of schizophrenia, leading to a new peptide drug targ...
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
